NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have received a consensus recommendation of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, one has assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $14.00.

Several research analysts recently commented on the stock. Zacks Research upgraded shares of NeuroSense Therapeutics to a “hold” rating in a research note on Wednesday, October 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a report on Monday, December 22nd. Noble Financial upgraded NeuroSense Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Wall Street Zen raised NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Two Sigma Investments LP purchased a new stake in shares of NeuroSense Therapeutics during the third quarter valued at $26,000. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics in the second quarter valued at about $54,000. Finally, Squarepoint Ops LLC increased its holdings in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares during the period. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Stock Up 2.0%

Shares of NRSN stock opened at $0.96 on Friday. The stock’s 50-day moving average is $0.97 and its 200 day moving average is $1.19. NeuroSense Therapeutics has a 1-year low of $0.68 and a 1-year high of $2.60.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.